Ceribell (NASDAQ:CBLL) saw its stock price surge 5.04% in after-hours trading on Tuesday, following the release of its impressive second-quarter 2025 earnings report. The medical technology company outperformed analysts' expectations and raised its full-year revenue guidance, sparking investor optimism.

For the second quarter, Ceribell reported revenue of $21.2 million, surpassing the analyst consensus estimate of $20.528 million by 3.27%. The company's earnings per share (EPS) came in at $(0.38), beating the expected $(0.40) by 4.52%. This better-than-anticipated performance demonstrates Ceribell's ability to execute its growth strategy effectively in the competitive medical device market.

Adding to the positive sentiment, Ceribell raised its full-year 2025 revenue guidance to a range of $85-$88 million. This upward revision suggests strong confidence in the company's growth trajectory and potential market expansion for its innovative neurological monitoring solutions. The combination of robust quarterly results and an optimistic outlook appears to have fueled the significant after-hours stock price appreciation, as investors reevaluate Ceribell's future prospects.